Search results
May 13, 2024 · Founded in 2015, Excision BioTherapeutics is a biotechnology company leveraging proprietary, CRISPR-based gene-editing technology and collaborative partnerships with leading research institutions to develop and advance transformative therapies designed to improve the lives of patients living with viral infectious diseases.--
Located in Watertown, MA, Excision BioTherapeutics, Inc. is a biotechnology company developing CRISPR-based therapies intended for the treatment of viral infectious diseases. We are focused on improving the lives of chronically ill patients by excising viral genomes from infected individuals.
Excision BioTherapeutics’ dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction and resulting in a potentially curative approach. We are advancing the first and only technology in history to remove human immunodeficiency virus (HIV) genomes from animals and generate curative treatments for HIV1.
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral...
Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection. The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation.
Oct 25, 2023 · Excision’s pipeline unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies for Herpes virus, Hepatitis B virus and JC virus, which causes PML.
Jul 20, 2023 · Excision BioTherapeutics EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and...
Sep 15, 2022 · Excision’s pipeline unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies for Herpes Virus, JC Virus, which causes PML, and Hepatitis B virus.
Aug 17, 2023 · Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1
May 13, 2024 · Excision BioTherapeutics, Inc. develops CRISPR-based medicines as potential cures for serious chronic viral infectious diseases based on its proprietary multiplexed gene editing platform that...
